Mereo Biopharma Group Plc - ADR

NASDAQ:MREO 4:00:00 PM EDT

1.73

-0.03 (-1.70%)

7:59:43 PM EDT: $1.74 +0.01 (+0.58%)

Market Cap (Intraday)	275.08M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$11.67 Million
Adjusted EPS	-$0.01

See more estimates

10-Day MA	$1.77
50-Day MA	$1.74
200-Day MA	$2.52

See more pivots

Mereo Biopharma Group Plc - ADR Stock, NASDAQ:MREO

1 Cavendish Place, 4th Floor, London, Greater London W1G 0QF

United Kingdom

Phone: +44.333.023.7300

Number of Employees: 33

http://www.mereobiopharma.com

Description

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.